Avid Bioservices Inc (CDMO)

[biopharm]

CSF1R Antibody
LY3022855, IMC-CS4

CSF1R Antibody
Pixley FJ and Stanley ER1
Target

Colony-stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), is a cell-surface receptor for its ligands, colony-stimulating factor 1 (CSF1) and IL-34.1,2 CSF1R plays an important role as regulator of the development, morphology, survival, and functions of tissue macrophages as well as tumor-associated macrophages (TAMs). CSF1 is involved in the recruitment and survival of macrophages in tumors. Increased CSF1 expression is implicated in tumor progression and metastasis, and is associated with poor prognosis in some cancers.3
Molecule

LY3022855 (IMC-CS4) is a human IgG1 monoclonal antibody designed to target the CSF1R, preventing ligands CSF1 and IL-342 from binding to the receptor and inhibiting TAMs from receiving CSF1 signals, decreasing their survival and relieving the effect of TAMs in the tumor.4
Clinical Development

LY3022855 (IMC-CS4) is being investigated in phase I clinical trials, including a collaboration clinical trial with another immuno-oncology agent.

http://lillyoncologypipeline.com/molecule/csf-1-r-antibody/overview

-----------

Locations
United States, California
Cedars Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact 646-888-5440
Principal Investigator: Heather McArthur
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact 646-422-4632
Principal Investigator: Karen Autio
Sponsors and Collaborators
Eli Lilly and Company

https://clinicaltrials.gov/ct2/show/NCT02265536

-----------

Hmmmmm....anyone sense PS Targeting